<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7059311/results/search/drug/results.xml">
  <result pre="The following regimens were administered based on international recommendations [17]:" exact="sofosbuvir" post="(SOF) plus ribavirin (RBV); SOF plus simeprevir (SMV) ± RBV; SOF"/>
  <result pre="were administered based on international recommendations [17]: sofosbuvir (SOF) plus" exact="ribavirin" post="(RBV); SOF plus simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV;"/>
  <result pre="international recommendations [17]: sofosbuvir (SOF) plus ribavirin (RBV); SOF plus" exact="simeprevir" post="(SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus daclatasvir (DCV) ± RBV;"/>
  <result pre="(SOF) plus ribavirin (RBV); SOF plus simeprevir (SMV) ± RBV; SOF plus" exact="ledipasvir" post="(LDV) ± RBV; SOF plus daclatasvir (DCV) ± RBV; ombitasvir (OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV,"/>
  <result pre="SOF plus simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus" exact="daclatasvir" post="(DCV) ± RBV; ombitasvir (OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV, glecaprevir (GLE) plus pibrentasvir"/>
  <result pre="simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus daclatasvir (DCV) ± RBV;" exact="ombitasvir" post="(OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV, glecaprevir (GLE) plus pibrentasvir (PIB), grazoprevir"/>
  <result pre="(DCV) ± RBV; ombitasvir (OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV, glecaprevir (GLE) plus pibrentasvir (PIB)," exact="grazoprevir" post="(GRZ) plus elbasvir (EBR) ± RBV, SOF plus velpatasvir (VEL) ± RBV. Use"/>
  <result pre="plus pibrentasvir (PIB), grazoprevir (GRZ) plus elbasvir (EBR) ± RBV, SOF plus" exact="velpatasvir" post="(VEL) ± RBV. Use of RBV was based on clinical judgement"/>
  <result pre="differences between the two groups were found regarding the referred" exact="alcohol" post="consumption. Table 2 Clinical characteristics concerning psychiatric disorders at"/>
  <result pre="(23.3%) &amp;lt; 0.001 Methadone 11 (7.6%) 1 (1%) 10 (23.3%) &amp;lt; 0.001" exact="Buprenorphine" post="1 (0.7%) 1 (1%) 0 1.000 Referred alcohol consumption,n(%)"/>
  <result pre="(23.3%) &amp;lt; 0.001 Buprenorphine 1 (0.7%) 1 (1%) 0 1.000 Referred" exact="alcohol" post="consumption,n(%) 5 (3.5%) 4 (4%) 1 (2.3%) 1.000 Legend:a-social"/>
  <result pre="(83.3%) patients were in treatment with protease inhibitors: one with" exact="atazanavir" post="unboosted, two with lopinavir/ritonavir, two with darunavir/ritonavir. Of the"/>
  <result pre="for Adverse Events CYP Cytochrome DAAs Direct-acting Antiviral Agents DCV" exact="Daclatasvir" post="DDIs Drug-drug interactions DSV Dasabuvir EBR Elbasvir EMA European"/>
  <result pre="LDV Ledipasvir MSM Man who have sex with man OBV" exact="Ombitasvir" post="PIB Pibrentasvir PP Per-protocol PTV/r Paritaprevir/ritonavir RBV Ribavirin SAEs"/>
  <result pre="man OBV Ombitasvir PIB Pibrentasvir PP Per-protocol PTV/r Paritaprevir/ritonavir RBV" exact="Ribavirin" post="SAEs Severe Adverse events SD Standard Deviation SMV Simeprevir"/>
  <result pre="RBV Ribavirin SAEs Severe Adverse events SD Standard Deviation SMV" exact="Simeprevir" post="SOF Sofosbuvir SVR Sustained Virological Response VEL Velpatasvir VOX"/>
  <result pre="SAEs Severe Adverse events SD Standard Deviation SMV Simeprevir SOF" exact="Sofosbuvir" post="SVR Sustained Virological Response VEL Velpatasvir VOX Voxilaprevir Publisher’s"/>
  <result pre="Deviation SMV Simeprevir SOF Sofosbuvir SVR Sustained Virological Response VEL" exact="Velpatasvir" post="VOX Voxilaprevir Publisher’s Note Springer Nature remains neutral with"/>
  <result pre="sustained virological response after treatment with pegylated interferon α-2a and" exact="ribavirin" post="in patients infected with HCV genotypes 2 and 3PLoS"/>
 </snippets>
</snippetsTree>
